Drug Database
SU

sumatriptan succinate (sc) (DFN 11 / Zembrace SymTouch / DFN11)

✓ Approved

Upsher-Smith Laboratories, LLC. · HTR1B · 小分子

什么是 sumatriptan succinate (sc)?

sumatriptan succinate (sc) 是一种小分子,由Upsher-Smith Laboratories, LLC.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名DFN 11, Zembrace SymTouch, DFN11
公司Upsher-Smith Laboratories, LLC.
药物类别小分子
分子靶点HTR1B, HTR1D
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

sumatriptan succinate (sc) 作用于 2 个分子靶点:

HTR1B5-hydroxytryptamine receptor 1B (HTR1DB, 5-HT1DB)
HTR1D5-hydroxytryptamine receptor 1D (HTR1DA, HT1DA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sumatriptan succinate (sc) 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersMigraine✓ Approved

相关研究文献

PubMedNature2026-11-19

TransA-MERFISH reveals divergent post-retinal direction-selective circuits.

Wang Fei F, Zhang Lin L, Chang Siyuan S, Liu Can C et al.

A major goal in neuroscience is to map the transformation of information as it flows through the brain. For example, neurons at many levels of the visual hierarchy are attuned to motion direction1-5. However, links between motion-selective computations and cell types at various stages of the visual hierarchy remain unidentified. A key first step in delineating these relationships is to map the wiring diagrams that connect different motion-selective cell types. Here we establish a systematic, cell-type-specific circuit-mapping method, combining an anterograde trans-neuronal fluorescent tracer (mWGA-mCherry)6 with spatial transcriptomics (multiplexed error-robust fluorescence in situ hybridization (MERFISH))7,8 to establish TransA-MERFISH. We used TransA-MERFISH to comprehensively map the synaptic target cell types of four retinal ganglion cell subclasses in superior colliculus (SC) at cell-type resolution. These experiments unexpectedly revealed that retinal on-off direction-selective ganglion cells (ooDSGCs) innervate several direction-selective SC cell types, but do not innervate a SC cell type that was previously reported to display strong direction-selective responses. We validated these results using orthogonal approaches and demonstrated the sensitivity and specificity of TransA-MERFISH. Functional studies of SC activity before and after ablation of retinal direction-selective circuits confirmed that these computationally distinct, ooDSGC-dependent and -independent direction-selective cell types are commingled in SC. Together, our study establishes TransA-MERFISH as a robust framework for mapping wiring diagrams at the cell-type level and uncovers divergent computational mechanisms of motion detection in early visual processing.

PMID 43052438
阅读全文 →
PubMedNPJ digital medicine2026-11-19

Understanding mechanistic role of structural and functional connectivity in tau propagation through multilayer modeling.

Dan Tingting T, Huang Xinwei X, Ding Jiaqi J, Zheng Yinggang Y et al.

Emerging neuroimaging evidence shows that pathological tau proteins build up along specific brain networks, suggesting that large-scale network architecture plays a key role in the progression of Alzheimer's disease (AD). However, how the interaction between structural (SC) and functional connectivity (FC) is associated with tau propagation remains largely unexplored. Using longitudinal neuroimaging data, we develop a multi-layer graph diffusion model to investigate this interplay. We identify a regionally asymmetric pattern, FC dominates tau accumulation in subcortical, insular, and frontotemporal regions, whereas SC prevails in occipital, parietal, and limbic areas. The principal conduit of tau propagation shifts from FC-mediated spread in early stages to SC-constrained diffusion as the disease advances. Furthermore, these propagation patterns correlate with regional expression of AD-associated genes (e.g., CHUK, TMEM106B, MCL1, NOTCH1, TH) and are selectively modulated by risk factors like APOE genotype and biological sex. By disentangling these dynamic pathways, our framework enables personalized trajectory prediction and refined patient stratification. These findings offer mechanistic insights into selective regional vulnerability, providing a quantitative basis for stage-specific therapeutic targeting and the optimization of clinical trial designs through network-based biomarkers. Our results are validated in an independent cohort, yielding consistent findings.

PMID 43052424
阅读全文 →
PubMedCancer prevention research (Philadelphia, Pa.)2026-11-19

CONNECT: Smoking Cessation Among Individuals Receiving Lung Cancer Screening: A Pilot Study.

Walsh Judith M E JME, Kaplan Celia P CP, Brown James J, Trivedi Neil N et al.

Lung cancer screening (LCS) is recommended for high-risk individuals. Little is known about how best to promote smoking cessation (SC) among individuals receiving LCS. We conducted a pilot randomized controlled trial to assess feasibility and acceptability of a novel SC intervention, CONNECT, among individuals undergoing LCS. CONNECT includes an interactive Video Doctor providing individually tailored information and proactive outreach using brief telephone calls and text messaging. We tested CONNECT among a diverse population of people who smoke in two health care settings. Participants were randomized to CONNECT or usual care. The primary outcomes were feasibility and acceptability. Secondary outcomes included smoking status at 3 months, quit attempts, and utilization of evidence-based SC resources, including pharmacotherapy. Among 372 eligible individuals, 76 (20.4%) agreed to participate. A total of 64 completed the study, for a retention rate of 84% (64/76). Although differences were not statistically significant, more participants in the intervention group rated the video doctor (38.7% vs 20.0%) and proactive outreach (51.5% vs 37.9%) as very/extremely helpful. CONNECT participants were more likely to recommend the program to friends and family who smoke (84.6% vs 73.9%). Positive themes describing CONNECT were accountbility, motivational, informative, helpful reminders and positive interactions with personnel. Smoking outcomes (self-reported 7 day abstinence) did not differ although numbers were small (2/35 (5.7%) vs 3/29 (10.3%) people who smoke). In conclusion, a pilot study of CONNECT among a diverse population of high-risk people who smoke undergoing LCS was feasible and most would recommend it to family/friends who smoke.

PMID 43053675
阅读全文 →
PubMedJournal of inflammation (London, England)2026-11-19

Itaconate as a central node in immunometabolism and inflammatory control.

Lin Jingjing J, Wang Gang G, Zi Fuming F

Mitochondria serve as central regulators of cellular bioenergetics and inflammatory signaling, integrating metabolic status with immune responses. Disruption of mitochondrial homeostasis, including altered tricarboxylic acid cycle dynamics, redox imbalance, and aberrant reactive oxygen species production, contributes to persistent inflammation and disease pathogenesis. Among emerging mitochondrial immunometabolic regulators, the IRG1/ACOD1-derived metabolite itaconate has gained attention as a critical molecular integrator linking mitochondrial metabolism to inflammatory control. This review systematically summarizes the biosynthesis of itaconate and its role in mitochondrial metabolic remodeling during inflammation. Itaconate reshapes the tricarboxylic acid cycle and inhibits succinate dehydrogenase, thereby limiting mitochondrial reactive oxygen species generation and preventing amplification of pro-inflammatory signaling. Through covalent modification of KEAP1, it activates the NRF2 antioxidant program, while concurrently restraining NLRP3 inflammasome activation, establishing a mitochondrial metabolic checkpoint that constrains excessive immune activation. Beyond acute metabolic regulation, itaconate coordinates sustained immunoregulatory programs via the ATF3-IκBζ transcriptional axis, autophagy-lysosome system modulation, and epigenetic reprogramming. We further integrate cell-type-specific effects of itaconate across macrophages, dendritic cells, T cells, and neutrophils, and discuss how mitochondrial immunometabolic dysregulation contributes to chronic inflammatory and metabolic disorders. By positioning the IRG1-itaconate axis within the broader framework of mitochondrial immunometabolism, this review highlights mitochondria as a central hub linking metabolic remodeling with inflammatory regulation. Targeting mitochondrial metabolic checkpoints such as the itaconate pathway may provide promising therapeutic strategies for restoring immune homeostasis and treating inflammation-associated diseases.

PMID 43053064
阅读全文 →
PubMedCell death discovery2026-11-18

Succinate exacerbates obesity-associated osteoarthritis: mitochondrial dysfunction mediated by SUCNR1 activation and succinylation modification.

Hong Haofeng H, Chen Longting L, Zhong Yiming Y, Yang Zihuan Z et al.

Osteoarthritis (OA) is the most prevalent degenerative joint disease and is closely related to obesity. The molecular mechanisms underlying obesity-induced metabolic alterations that lead to cartilage degeneration have not been fully elucidated. Succinate, a key intermediate in the Krebs cycle, exhibits signaling functions that extend beyond its traditional metabolic role. This study demonstrates that succinate is significantly accumulated in the knee joint of obesity-associated OA. Succinate exacerbates obesity-associated cartilage degeneration through a combination of extracellular and intracellular pathways, which converge on mitochondrial dysfunction. Mechanistically, extracellular succinate activates G protein-coupled receptor succinate receptor-1 (SUCNR1), triggering mitochondrial fission and activation of the cGAS-STING pathway. Intracellular succinate reduces NADPH levels and promotes mitochondrial reactive oxygen species (mtROS) accumulation, in association with increased IDH2 succinylation. Additionally, sirtuin 5 (SIRT5) acts as an IDH2 desuccinylase and exerts a protective effect against intracellular succinate-induced cartilage degeneration. To target both intracellular and extracellular succinate, the phenylboronic acid-modified gelatin hydrogel is designed to load the SUCNR1 inhibitor 5 g and the SIRT5 agonist puerarin. This injectable ROS-responsive system targeting succinate exhibits remarkable therapeutic efficacy in vivo. These findings suggest that targeting succinate provides a novel therapeutic strategy for obesity-associated OA. Created with BioRender.com.

PMID 43045682
阅读全文 →
PubMedBMC cancer2026-11-18

Gut microbiota dysbiosis-associated succinate accumulation is linked to gastric cancer progression and macrophage-related tumour microenvironment remodelling.

Gao Jie J, Bao Zhixian Z, Chen Xinhong X, Ren Qian Q et al.

Gastric cancer (GC) is a lethal gastrointestinal malignancy regulated by genetic alterations and tumour microenvironment (TME) remodelling. Gut microbiota metabolites can regulate tumour progression through the microbiota-metabolite-immune axis. However, the relationship among GC-associated gut microbiota dysbiosis, succinate accumulation, and macrophage-related immune features remains unclear. This study aimed to investigate whether GC-associated gut microbiota dysbiosis is linked to succinate accumulation and to elucidate the role of succinate in tumour progression and immune microenvironment remodelling. We screened for GC-related and succinate-related microbes using the Peryton and GutMGene databases. Faecal 16S rRNA sequencing and untargeted metabolomics were performed on tumour-bearing and control mice. Network-based target analysis was used to identify potential succinate-related signalling pathways in GC. The effects of succinate on GC cell proliferation, colony formation, migration/invasion, apoptosis, and tumour growth were evaluated using in vitro experiments and a subcutaneous tumour-bearing model. Public single-cell RNA sequencing (scRNA-seq) data were analysed to characterise the GC immune microenvironment, macrophage subset distribution, and CXC chemokine receptor 4 (CXCR4) expression. Bone marrow-derived macrophages (BMDMs) were used to verify the regulatory effects of succinate on CXCR4 expression. GC was associated with significant gut microbiota remodelling and increased faecal succinate levels. Succinate promotes GC cell proliferation, colony formation, migration/invasion, cell survival, and in vivo tumour growth. Multiplex cytokine and chemokine assays revealed upregulated CXCL12 and downregulated CXCL10 levels in succinate-treated tumour tissues. Network analysis revealed that succinate-related targets were enriched in metabolic reprogramming, hypoxic responses, inflammatory immune regulation, and hypoxia-inducible factor-1 and peroxisome proliferator-activated receptor signalling pathways. scRNA-seq analysis indicated enhanced immune-stromal infiltration, intensified intercellular communication, expansion of SPP1⁺ macrophages, and CXCR4-high features in macrophages within GC tissues. In vitro experiments confirmed that succinate upregulated CXCR4 mRNA expression in BMDMs. These findings suggest that GC-bearing status is associated with gut microbiota dysbiosis and faecal succinate accumulation, and that succinate may contribute to malignant phenotypes and CXCL12/CXCR4-related macrophage features in vitro and in a subcutaneous tumour model. However, the current data do not directly demonstrate that microbiota-derived succinate reaches the native gastric tumour microenvironment or that CXCL12/CXCR4-dependent macrophage remodelling is required for tumour growth. Further blocking, rescue, and orthotopic or spontaneous gastric cancer model studies are needed to validate this candidate mechanism in the native gastric tumour microenvironment.

PMID 43045991
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多sumatriptan succinate (sc)